Vaccine Stocks Alert: Has RFK Jr.’s CDC Panel Shakeup Sent Retail Traders To The Sidelines?

Published 10-06-2025, 11:44 am
Updated 10-06-2025, 12:16 pm
© Reuters.  Vaccine Stocks Alert: Has RFK Jr.'s CDC Panel Shakeup Sent Retail Traders To The Sidelines?

Stocktwits - Several vaccine maker stocks slipped in after-hours trading Monday after Health Secretary Robert F. Kennedy Jr. announced a sweeping overhaul of the CDC’s Advisory Committee for Immunization Practices (ACIP), sparking concerns among retail traders about the direction of vaccine policy in the United States.

After the closing bell, Pfizer (NYSE:PFE) shares dropped nearly 1.3%, while Moderna (NASDAQ:MRNA) fell over 1%. BioNTech (NASDAQ:BNTX) dipped 0.26%, and GlaxoSmithKline edged lower by 0.12%.

In a Wall Street Journal op-ed published Monday, Kennedy said the Department of Health and Human Services would retire all 17 current members of the ACIP, citing what he called a "crisis of public trust."

He argued that restoring confidence in vaccines and public health institutions required more than incremental changes.

"Vaccines have become a divisive issue… That is why, under my direction, HHS is putting the restoration of public trust above any pro- or antivaccine agenda," Kennedy wrote.

"A clean sweep is needed to re-establish public confidence in vaccine science."

Kennedy, a longtime critic of vaccine mandates, explained that without this move, the current Trump administration could not appoint a majority of new committee members until 2028.

The ACIP shakeup, he said, was a necessary first step in reshaping federal health guidance.

On Stocktwits, retail trader sentiment reflected growing unease.

Moderna’s sentiment turned more ’bearish,’ while BioNTech’s slipped from ’bullish’ to ’bearish.’ GSK’s sentiment dropped to ’bearish’ from ’neutral,’ and Pfizer’s remained ’neutral.’

Novavax (NASDAQ:NVAX) bucked the trend and rose in extended trading, but retail sentiment on the stock remained ’bearish.’

BNTX sentiment and message volume as of Jun 9. | source: StocktwitsMRNA sentiment and message volume as of Jun 9. | source: StocktwitsGSK sentiment and message volume as of Jun 9. | source: StocktwitsPFE sentiment and message volume as of Jun 9. | source: StocktwitsNVAX sentiment and message volume as of Jun 9. | source: StocktwitsThe advisor overhaul is the latest in a string of dramatic policy changes since Kennedy took office as HHS chief.

Under his leadership, the department has stopped recommending routine COVID-19 vaccines for healthy children and pregnant women and has canceled research programs to prevent future pandemics.

Retail traders now appear to be reassessing their positioning in vaccine stocks, unsure how far the policy pivot could go.

This content is provided by Stocktwits

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.